Dipal Doshi Sells 1,800 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi sold 1,800 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.00, for a total value of $27,000.00. Following the sale, the chief executive officer now directly owns 338,575 shares in the company, valued at approximately $5,078,625. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Entrada Therapeutics Trading Up 2.5 %

NASDAQ:TRDA opened at $15.70 on Wednesday. The company has a market capitalization of $530.03 million, a P/E ratio of 24.92 and a beta of -0.38. The firm has a 50-day moving average price of $13.42 and a two-hundred day moving average price of $14.15. Entrada Therapeutics, Inc. has a twelve month low of $10.62 and a twelve month high of $18.44.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.22). Entrada Therapeutics had a return on equity of 9.73% and a net margin of 14.42%. The business had revenue of $41.85 million for the quarter, compared to analysts’ expectations of $27.82 million. On average, equities research analysts predict that Entrada Therapeutics, Inc. will post -0.14 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research report on Monday, March 18th.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently made changes to their positions in TRDA. New York State Teachers Retirement System acquired a new stake in shares of Entrada Therapeutics during the first quarter valued at $27,000. Allspring Global Investments Holdings LLC purchased a new position in Entrada Therapeutics in the 3rd quarter valued at about $44,000. Acadian Asset Management LLC purchased a new position in Entrada Therapeutics in the 1st quarter valued at about $79,000. Tower Research Capital LLC TRC boosted its stake in shares of Entrada Therapeutics by 476.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,780 shares of the company’s stock worth $87,000 after purchasing an additional 4,777 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Entrada Therapeutics by 27.7% during the fourth quarter. SG Americas Securities LLC now owns 11,714 shares of the company’s stock worth $177,000 after buying an additional 2,540 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.